{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:29:11Z","timestamp":1790980151449,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["2018-2021"],"award-info":[{"award-number":["2018-2021"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Nordic cancer union, Denmark","award":["194914"],"award-info":[{"award-number":["194914"]}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","award":["CAN-2021\\1848 (KS)"],"award-info":[{"award-number":["CAN-2021\\1848 (KS)"]}],"id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles. Compared to reference CA19-9 and CA125 immunoassays, nanoparticle aided detection using MUC16, Ma695 and STn antibodies and lectin WGA provided, both separately and combined, improved discrimination of EOC and borderline cancers from benign samples when applied to 60 cyst fluid specimens. When applied to a panel of 44 serum samples (EOC N\u2009=\u200924, healthy and benign samples N\u2009=\u200920) two assays, CA19-9<jats:sup>Ma695<\/jats:sup> and CA19-9<jats:sup>MUC1<\/jats:sup>, stood out with equally superior separations (p-values\u2009&lt;\u200910<jats:sup>\u20138<\/jats:sup>) of the two groups compared to conventional CA19-9 immunoassay (p-value 0.03).Eu<jats:sup>+3<\/jats:sup> -NP based CA19-9<jats:sup>MUC16<\/jats:sup>, CA19-9<jats:sup>Ma695<\/jats:sup>, CA19-9<jats:sup>STn<\/jats:sup> and CA19-9<jats:sup>WGA<\/jats:sup> show promise for improved EOC detection when applied to ascites &amp; cyst fluids. When applied to circulation-derived samples, the two MUC1 based assays, CA19-9<jats:sup>Ma695<\/jats:sup> and CA19-9<jats:sup>Ma552<\/jats:sup> outperformed other assay constructs. Our results call for further validation in larger EOC cohorts preferentially with early stage ovarian cancers and all major histotypes against commonly occurring benign conditions.<\/jats:p>","DOI":"10.1038\/s41598-025-86735-z","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T06:27:26Z","timestamp":1737786446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Shamima Afrin","family":"Ruma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufus","family":"Vinod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Huhtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Leivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Sundfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"86735_CR1","unstructured":"Diagnosis and Management of Ovarian Cancer - American Family Physician. https:\/\/www.aafp.org\/afp\/2016\/0601\/p937.html."},{"key":"86735_CR2","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397, 2182\u20132193. https:\/\/doi.org\/10.1016\/S0140-6736(21)00731-5 (2021).","journal-title":"Lancet"},{"key":"86735_CR3","doi-asserted-by":"publisher","first-page":"15636","DOI":"10.3390\/ijms140815636","volume":"14","author":"R Saldova","year":"2013","unstructured":"Saldova, R. et al. Exploring the glycosylation of serum CA125. Int. J. Mol. Sci. 14, 15636\u201315654. https:\/\/doi.org\/10.3390\/ijms140815636 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"86735_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2217\/bmm.15.47","volume":"9","author":"SO Abu Hassan","year":"2015","unstructured":"Abu Hassan, S. O. et al. Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation. Biomark. Med. 9, 911\u2013923. https:\/\/doi.org\/10.2217\/bmm.15.47 (2015).","journal-title":"Biomark. Med."},{"key":"86735_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1155\/2008\/601583","volume":"25","author":"R Saldova","year":"2008","unstructured":"Saldova, R., Wormald, M. R., Dwek, R. A. & Rudd, P. M. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis. Markers 25, 219\u2013232. https:\/\/doi.org\/10.1155\/2008\/601583 (2008).","journal-title":"Dis. Markers"},{"key":"86735_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ijgo.12139","volume":"137","author":"YQ Wang","year":"2017","unstructured":"Wang, Y. Q. et al. Use of cancer antigen 125, cancer antigen 19\u20139, and the neutrophil-to-lymphocyte ratio to diagnose mature cystic teratoma with torsion. Int. J. Gynecol. Obstet. 137, 332\u2013337. https:\/\/doi.org\/10.1002\/ijgo.12139 (2017).","journal-title":"Int. J. Gynecol. Obstet."},{"key":"86735_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/gyno.2000.5811","volume":"78","author":"MJA Engelen","year":"2000","unstructured":"Engelen, M. J. A. et al. Serum CA 125, carcinoembryonic antigen, and CA 19\u20139 as tumor markers in borderline ovarian tumors. Gynecol. Oncol. 78, 16\u201320. https:\/\/doi.org\/10.1006\/gyno.2000.5811 (2000).","journal-title":"Gynecol. Oncol."},{"key":"86735_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/S00428-016-1929-6","volume":"468","author":"S Ricardo","year":"2016","unstructured":"Ricardo, S. et al. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch. 468, 715\u2013722. https:\/\/doi.org\/10.1007\/S00428-016-1929-6 (2016).","journal-title":"Virchows Arch."},{"key":"86735_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/J.1365-2559.2010.03667.X","volume":"57","author":"CHMJ Van Elssen","year":"2010","unstructured":"Van Elssen, C. H. M. J. et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57, 597\u2013606. https:\/\/doi.org\/10.1111\/J.1365-2559.2010.03667.X (2010).","journal-title":"Histopathology"},{"key":"86735_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/PR3010474","volume":"12","author":"K Chen","year":"2013","unstructured":"Chen, K. et al. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J. Proteome Res. 12, 1408\u20131418. https:\/\/doi.org\/10.1021\/PR3010474 (2013).","journal-title":"J. Proteome Res."},{"key":"86735_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1091-255X(97)80097-2","volume":"1","author":"F Safi","year":"1997","unstructured":"Safi, F., Schlosser, W., Kolb, G. & Beger, H. G. Diagnostic value of CA 19\u20139 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J. Gastrointest. Surg. 1, 106\u2013112. https:\/\/doi.org\/10.1016\/S1091-255X(97)80097-2 (1997).","journal-title":"J. Gastrointest. Surg."},{"key":"86735_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBCAN.2020.188409","volume":"1875","author":"G Luo","year":"2021","unstructured":"Luo, G. et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim. Biophys. Acta - Rev. Cancer 1875, 188409. https:\/\/doi.org\/10.1016\/J.BBCAN.2020.188409 (2021).","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"86735_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/AJG.2016.482","volume":"112","author":"S Kaur","year":"2017","unstructured":"Kaur, S. et al. A Combination of MUC5AC and CA19-9 Improves the diagnosis of pancreatic cancer: A multicenter study. Am. J. Gastroenterol. 112, 172\u2013183. https:\/\/doi.org\/10.1038\/AJG.2016.482 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"86735_CR14","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1002\/PMIC.201000827","volume":"11","author":"T Yue","year":"2011","unstructured":"Yue, T. et al. Identification of blood-protein carriers of the CA 19\u20139 antigen and characterization of prevalence in pancreatic diseases. Proteomics 11, 3665\u20133674. https:\/\/doi.org\/10.1002\/PMIC.201000827 (2011).","journal-title":"Proteomics"},{"key":"86735_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029180","author":"T Yue","year":"2011","unstructured":"Yue, T. et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19\u20139 Antigen on specific protein carriers. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0029180 (2011).","journal-title":"PLoS ONE"},{"key":"86735_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1074\/MCP.M800313-MCP200","volume":"8","author":"C Kuk","year":"2009","unstructured":"Kuk, C. et al. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol. Cell. Proteomics 8, 661\u2013669. https:\/\/doi.org\/10.1074\/MCP.M800313-MCP200 (2009).","journal-title":"Mol. Cell. Proteomics"},{"key":"86735_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/00016340802443830","volume":"88","author":"AL Petri","year":"2009","unstructured":"Petri, A. L. et al. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet. Gynecol. Scand. 88, 18\u201326. https:\/\/doi.org\/10.1080\/00016340802443830 (2009).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"86735_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/PRCA.200900042","volume":"4","author":"AL Petri","year":"2010","unstructured":"Petri, A. L. et al. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics. Clin. Appl. 4, 304\u2013314. https:\/\/doi.org\/10.1002\/PRCA.200900042 (2010).","journal-title":"Proteomics. Clin. Appl."},{"key":"86735_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1021\/PR0703223","volume":"7","author":"L Gortzak-Uzan","year":"2008","unstructured":"Gortzak-Uzan, L. et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7, 339\u2013351. https:\/\/doi.org\/10.1021\/PR0703223 (2008).","journal-title":"J. Proteome Res."},{"key":"86735_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/NRC3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540\u2013555. https:\/\/doi.org\/10.1038\/NRC3982 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"86735_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/J.TIBS.2015.04.004","volume":"40","author":"AP Corfield","year":"2015","unstructured":"Corfield, A. P. & Berry, M. Glycan variation and evolution in the eukaryotes. Trends Biochem. Sci. 40, 351\u2013359. https:\/\/doi.org\/10.1016\/J.TIBS.2015.04.004 (2015).","journal-title":"Trends Biochem. Sci."},{"key":"86735_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1559-0275-9-14\/TABLES\/4","volume":"9","author":"B Kristjansdottir","year":"2012","unstructured":"Kristjansdottir, B. et al. Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. Clin. Proteomics 9, 1\u20139. https:\/\/doi.org\/10.1186\/1559-0275-9-14\/TABLES\/4 (2012).","journal-title":"Clin. Proteomics"},{"key":"86735_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1373\/CLINCHEM.2016.257691","volume":"62","author":"K Gidwani","year":"2016","unstructured":"Gidwani, K. et al. A nanoparticle-Lectin immunoassay Improves discrimination of serum CA125 from malignant and benign sources. Clin. Chem. 62, 1390\u20131400. https:\/\/doi.org\/10.1373\/CLINCHEM.2016.257691 (2016).","journal-title":"Clin. Chem."},{"key":"86735_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/JALM\/JFZ012","volume":"5","author":"L Salminen","year":"2020","unstructured":"Salminen, L. et al. Exploratory analysis of CA125-MGL and -STn glycoforms in the differential diagnostics of pelvic masses. J. Appl. Lab. Med. 5, 263\u2013272. https:\/\/doi.org\/10.1093\/JALM\/JFZ012 (2020).","journal-title":"J. Appl. Lab. Med."},{"key":"86735_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1373\/JALM.2018.028266","volume":"4","author":"K Gidwani","year":"2019","unstructured":"Gidwani, K. et al. Europium nanoparticle-based Sialyl-Tn monoclonal antibody discriminates epithelial ovarian cancer-associated ca125 from benign sources. J. Appl. Lab. Med. 4, 299\u2013310. https:\/\/doi.org\/10.1373\/JALM.2018.028266 (2019).","journal-title":"J. Appl. Lab. Med."},{"key":"86735_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.MAM.2019.11.001","author":"K Gidwani","year":"2020","unstructured":"Gidwani, K. et al. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Mol. Aspects Med. https:\/\/doi.org\/10.1016\/J.MAM.2019.11.001 (2020).","journal-title":"Mol. Aspects Med."},{"key":"86735_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/S42003-020-01191-X","author":"S Bayoumy","year":"2020","unstructured":"Bayoumy, S. et al. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125. Commun. Biol. https:\/\/doi.org\/10.1038\/S42003-020-01191-X (2020).","journal-title":"Commun. Biol."},{"key":"86735_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.34111","author":"S Jain","year":"2022","unstructured":"Jain, S. et al. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer. Int. J. Cancer  (2022).","journal-title":"Int. J. Cancer"},{"key":"86735_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.AB.2021.114283","author":"MK Islam","year":"2021","unstructured":"Islam, M. K. et al. Detection of bladder cancer with aberrantly fucosylated ITGA3. Anal. Biochem. https:\/\/doi.org\/10.1016\/J.AB.2021.114283 (2021).","journal-title":"Anal. Biochem."},{"key":"86735_CR30","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/jog.14427","volume":"46","author":"A Lertkhachonsuk","year":"2020","unstructured":"Lertkhachonsuk, A. et al. Serum CA19\u20139, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J. Obstet. Gynaecol. Res. 46, 2287\u20132291. https:\/\/doi.org\/10.1111\/jog.14427 (2020).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"86735_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CMAR.S155693","volume":"10","author":"F Chen","year":"2018","unstructured":"Chen, F., Shen, J., Wang, J., Cai, P. & Huang, Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: Diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag. Res. 10, 1313\u20131318. https:\/\/doi.org\/10.2147\/CMAR.S155693 (2018).","journal-title":"Cancer Manag. Res."},{"key":"86735_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00428-016-1929-6","volume":"468","author":"S Ricardo","year":"2016","unstructured":"Ricardo, S. et al. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch. 468, 715\u2013722 (2016).","journal-title":"Virchows Arch."},{"key":"86735_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/S00428-016-1929-6","author":"D Sexauer","year":"2022","unstructured":"Sexauer, D., Gray, E. & Zaenker, P. Tumour- associated autoantibodies as prognostic cancer biomarkers- a review. Autoimmun. Rev. https:\/\/doi.org\/10.1007\/S00428-016-1929-6 (2022).","journal-title":"Autoimmun. Rev."},{"key":"86735_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2015.12.003","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell. Mol. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.jcmgh.2015.12.003 (2016).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"86735_CR35","doi-asserted-by":"publisher","first-page":"e0219480","DOI":"10.1371\/journal.pone.0219480","volume":"14","author":"J Ter\u00e4v\u00e4","year":"2019","unstructured":"Ter\u00e4v\u00e4, J. et al. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15\u20133 (CA15-3) in human plasma. PLoS One 14, e0219480. https:\/\/doi.org\/10.1371\/journal.pone.0219480 (2019).","journal-title":"PLoS One"},{"key":"86735_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0219480","author":"J Ter\u00e4v\u00e4","year":"2019","unstructured":"Ter\u00e4v\u00e4, J. et al. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15\u20133 (CA15\u20133) in human plasma. PLoS One https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0219480 (2019).","journal-title":"PLoS One"},{"key":"86735_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.15175","volume":"5","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife 5, 1\u201318. https:\/\/doi.org\/10.7554\/eLife.15175 (2016).","journal-title":"Elife"},{"key":"86735_CR38","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1021\/ac001287l","volume":"73","author":"T Soukka","year":"2001","unstructured":"Soukka, T., H\u00e4rm\u00e4, H., Paukkunen, J. & L\u00f6vgren, T. Utilization of kinetically enhanced monovalent binding affinity by immunoassays based on multivalent nanoparticle-antibody bioconjugates. Anal. Chem. 73, 2254\u20132260. https:\/\/doi.org\/10.1021\/ac001287l (2001).","journal-title":"Anal. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86735-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86735-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T06:27:31Z","timestamp":1737786451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86735-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86735"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86735-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee Regionala etikpr\u00f6vningsn\u00e4mnden i G\u00f6teborg (Dnr 201\u201315) in Gothenburg and was performed in accordance with the Declaration of Helsinki and all its amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}],"article-number":"3171"}}